Effect of low-dose aspirin on platelet aggregation inhibition in patients with rheumatoid arthritis

Effect of low-dose aspirin on platelet aggregation inhibition in patients with rheumatoid arthritis


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: مهرزاد حاج علیلوی بناب , امیر قربانی حق جو , فروغ قاسمی , علیرضا خبازی اسکویی , آیدا مالک مهدوی

کلمات کلیدی: Aspirin, Thromboxane B2, Platelet Aggregation, Coronary Artery Disease, Rheumatoid Arthritis

نشریه: 0 , 4 , 7 , 2019

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله آیدا مالک مهدوی
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه بیماری های بافت همبند
کد مقاله 70515
عنوان فارسی مقاله Effect of low-dose aspirin on platelet aggregation inhibition in patients with rheumatoid arthritis
عنوان لاتین مقاله Effect of low-dose aspirin on platelet aggregation inhibition in patients with rheumatoid arthritis
ناشر 5
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق) Journal of Research in Clinical Medicine
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح چهار – سایر سایت های تخصصی
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Introduction:The risk for coronary artery disease (CAD) and mortality has increased in patients with rheumatoid arthritis (RA). Aspirin has anti-thrombotic effects and causes reduction in CAD occurrence in high-risk individuals. The objective of present project was evaluating the influence of low-dose aspirin on inhibition of platelet aggregation in patients with RA. Forty-eight subjects with RA diagnosed based on the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria and age- and sex-matched healthy participants were studied. All subjects received 81 mg/day aspirin for 10 days. Level of the serum thromboxane B2 (sTxB2), a permanent metabolite of thromboxane A2 (TxA2), was measured before and after therapy using enzyme-linked immunosorbent assay (ELISA) kit. The impotency to decrease sTxB2 production to less than 10 ng/ml indicates suboptimal suppression of platelet aggregation via aspirin. Low-dose aspirin decreased sTxB2 significantly compared with baseline in patients with RA [median interquartile range (IQR): 25.72 (11.78, 90.10) to 7.74 (5.80, 8.82), P < 0.001] and in healthy controls [median (IQR): 40.50 (33.25, 50.90) to 7.30 (4.75, 8.85), P < 0.001]. No remarkable changes were seen in sTxB2 between patients and controls after adjustment (P > 0.050). Pharmacologic influence of aspirin was suboptimal in 6.25% of cases in the presence of higher erythrocyte sedimentation rate (ESR) and in 2.7% of controls. Low-dose aspirin decreased sTxB2 significantly only in patients with Framingham Risk Score (FRS) < 10%. Low-dose aspirin decreased sTxB2 level and suppressed platelet aggregation and therefore, was effective in primary prevention of cardiovascular (CV) events in patients with RA; however, additional studies are required to reach accurate conclusions.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
مهرزاد حاج علیلوی بناباول
امیر قربانی حق جودوم
فروغ قاسمیسوم
علیرضا خبازی اسکوییچهارم
آیدا مالک مهدویپنجم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
jarcm-7-110.pdf1398/09/301003938دانلود